Search - tctmd.com

Displaying 1 - 20 of 89

Sort: Relevancy | Date

An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Presentation AHA 2016

PIONEER Trial: An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy

Presenter: Michael Gibson

November 15, 2016

News Conference News AHA 2016

PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad

Michael O'Riordan

November 15, 2016

AEGIS-I Trial: The Safety and Tolerability of CSL112

Presentation AHA 2016

The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Human ApoA-I, After Acute Myocardial Infarction: The ApoA-I Event reducingG in Ischemic Syndromes I Trial (AEGIS-I)

Presenter: Michael Gibson

November 15, 2016

News Conference News AHA 2016

Shaky FUTURE? FFR Takes a Hit With Mortality Signal in French Study

Michael O'Riordan

November 14, 2016

News Conference News AHA 2016

Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI

Todd Neale

November 14, 2016

Presentation TCT 2016

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, C. Michael Gibson

November 01, 2016

Presentation TCT 2016

Acute Anticoagulation Management and Bleeding Avoidance Strategies in the Chronic AF Patient Who Requires PCI

Presenter: David P. Faxon, C. Michael Gibson, Deepak L. Bhatt

November 01, 2016

Presentation TCT 2016

When and Which Antiplatelet Agent Should be Dropped When Using Oral Anticoagulant Therapy?

Presenter: David P. Faxon, C. Michael Gibson, Roxana Mehran

November 01, 2016

Presentation TCT 2016

Dosing Considerations of Oral Anticoagulant Therapy in the ACS and PCI Patient: Optimizing Efficacy While Minimizing Bleeding

Presenter: David P. Faxon, C. Michael Gibson

November 01, 2016

Presentation TCT 2016

General Overview and Highlights of the North American Consensus Document on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

Presenter: David P. Faxon, C. Michael Gibson, Dominick J. Angiolillo

November 01, 2016

Presentation TCT 2016

European Guidelines on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

Presenter: David P. Faxon, C. Michael Gibson, Davide Capodanno

November 01, 2016

Presentation TCT 2016

What Is Known (and What Is Not) About Discontinuing Aspirin or Clopidogrel in Patients on Chronic Oral Anticoagulants Plus DAPT

Presenter: David P. Faxon, C. Michael Gibson, Freek W.A. Verheugt

November 01, 2016

Presentation TCT 2016

The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus DAPT

Presenter: David P. Faxon, C. Michael Gibson, Christopher B. Granger

November 01, 2016

Presentation TCT 2016

Antiplatelet Therapy in Patients Who Need Anticoagulation: Current Guidelines, Ongoing Studies

Presenter: George D. Dangas, Debabrata Mukherjee, C. Michael Gibson

November 01, 2016

Presentation TCT 2016

Is There a Current Role for Intracoronary Lytics or GP IIb/IIIa Inhibitors During Primary PCI?

Presenter: Deepak L. Bhatt, Stefan K. James, C. Michael Gibson

October 31, 2016

Presentation TCT 2016

Opportunities and Risks of Data Sharing III: International Consortium Proposal

Presenter: C. Michael Gibson, A. Michael Lincoff, Philip James Devereaux

October 31, 2016

Presentation TCT 2016

Opportunities and Risks of Data Sharing II: ACCESS CV Proposal

Presenter: C. Michael Gibson, A. Michael Lincoff, Manesh R. Patel

October 31, 2016

Presentation TCT 2016

Opportunities and Risks of Data Sharing I: YODA Proposal

Presenter: C. Michael Gibson, A. Michael Lincoff, Harlan Krumholz

October 31, 2016

Presentation TCT 2016

The Moral Imperative and Potential Benefits of Data Sharing: Journalist Perspective

Presenter: C. Michael Gibson, A. Michael Lincoff, Eric D. Peterson

October 31, 2016

Presentation TCT 2016

Rationale for and Design of TWILIGHT and GLOBAL LEADERS: What I Expect the Findings to Be But What Wont Surprise Me!

Presenter: Jorge Gaspar, C. Michael Gibson

October 30, 2016

Advertisement

PIONEER Trial: An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy

PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad

The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Human ApoA-I, After Acute Myocardial Infarction: The ApoA-I Event reducingG in Ischemic Syndromes I Trial (AEGIS-I)

Shaky FUTURE? FFR Takes a Hit With Mortality Signal in French Study

Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

Acute Anticoagulation Management and Bleeding Avoidance Strategies in the Chronic AF Patient Who Requires PCI

When and Which Antiplatelet Agent Should be Dropped When Using Oral Anticoagulant Therapy?

Dosing Considerations of Oral Anticoagulant Therapy in the ACS and PCI Patient: Optimizing Efficacy While Minimizing Bleeding

General Overview and Highlights of the North American Consensus Document on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

European Guidelines on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

What Is Known (and What Is Not) About Discontinuing Aspirin or Clopidogrel in Patients on Chronic Oral Anticoagulants Plus DAPT

The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus DAPT

Antiplatelet Therapy in Patients Who Need Anticoagulation: Current Guidelines, Ongoing Studies

Is There a Current Role for Intracoronary Lytics or GP IIb/IIIa Inhibitors During Primary PCI?

Opportunities and Risks of Data Sharing III: International Consortium Proposal

Opportunities and Risks of Data Sharing II: ACCESS CV Proposal

Opportunities and Risks of Data Sharing I: YODA Proposal

The Moral Imperative and Potential Benefits of Data Sharing: Journalist Perspective

Rationale for and Design of TWILIGHT and GLOBAL LEADERS: What I Expect the Findings to Be But What Wont Surprise Me!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content